文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

非编码 RNA 在骨肉瘤中的作用:与耐药性的关系。

Noncoding RNAs in osteosarcoma: Implications for drug resistance.

机构信息

Department of Orthopedics, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China; Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan Province, China.

Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan Province, China.

出版信息

Cancer Lett. 2021 Apr 28;504:91-103. doi: 10.1016/j.canlet.2021.02.007. Epub 2021 Feb 12.


DOI:10.1016/j.canlet.2021.02.007
PMID:33587978
Abstract

Osteosarcoma is the most frequent bone malignancy in children and adolescents. Despite advances of surgery and chemotherapy in osteosarcoma over the past decades, overall survival rates of osteosarcoma have reached a plateau. The development of multi-drug resistance (MDR) has become the main obstacle in improving chemotherapeutic effects in osteosarcoma treatment. Therefore, understanding detailed mechanisms of chemoresistance and developing novel therapeutic targets to overcome chemoresistance are crucial to improve the prognosis of osteosarcoma patients. Accumulating evidence has proved that multiple noncoding RNAs (ncRNAs), including microRNAs (miRNAs), long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) play pivotal roles in osteosarcoma progression. Notably, a great number of ncRNAs are abnormally expressed and can regulate chemosensitivity through various mechanisms in osteosarcoma. In this review, we systematically summarize the roles of ncRNAs as well as the molecular mechanisms in modulating drug resistance of osteosarcoma and discuss the potential roles of ncRNAs as biomarkers and novel therapeutic targets for osteosarcoma.

摘要

骨肉瘤是儿童和青少年中最常见的骨恶性肿瘤。尽管在过去几十年中,骨肉瘤的手术和化疗取得了进展,但骨肉瘤的总体生存率已经达到了一个平台期。多药耐药(MDR)的发展已成为改善骨肉瘤治疗中化疗效果的主要障碍。因此,了解化疗耐药的详细机制并开发新的治疗靶点以克服化疗耐药性对于改善骨肉瘤患者的预后至关重要。越来越多的证据表明,多种非编码 RNA(ncRNA),包括 microRNAs(miRNAs)、长链非编码 RNA(lncRNA)和环状 RNA(circRNA),在骨肉瘤的进展中发挥着关键作用。值得注意的是,大量的 ncRNA 异常表达,并可以通过多种机制调节骨肉瘤的化疗敏感性。在这篇综述中,我们系统地总结了 ncRNA 在调节骨肉瘤耐药性中的作用及其分子机制,并讨论了 ncRNA 作为骨肉瘤生物标志物和新型治疗靶点的潜在作用。

相似文献

[1]
Noncoding RNAs in osteosarcoma: Implications for drug resistance.

Cancer Lett. 2021-4-28

[2]
Deciphering chemoresistance in osteosarcoma: Unveiling regulatory mechanisms and function through the lens of noncoding RNA.

Drug Dev Res. 2024-4

[3]
Competitive endogenous network of circRNA, lncRNA, and miRNA in osteosarcoma chemoresistance.

Eur J Med Res. 2023-9-16

[4]
Targeting the Wnt/β-catenin cascade in osteosarcoma: The potential of ncRNAs as biomarkers and therapeutics.

Pathol Res Pract. 2024-7

[5]
The emerging role of noncoding RNAs in colorectal cancer chemoresistance.

Cell Oncol (Dordr). 2019-7-29

[6]
Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.

Cancer Lett. 2016-9-5

[7]
Noncoding RNAs in drug-resistant pancreatic cancer: A review.

Biomed Pharmacother. 2020-11

[8]
Emerging roles of non-coding RNAs in the pathogenesis, diagnosis and prognosis of osteosarcoma.

Invest New Drugs. 2018-8-6

[9]
LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting Hexokinase 2.

Cancer Biomark. 2020

[10]
Analyzing the Interactions of mRNAs and ncRNAs to Predict Competing Endogenous RNA Networks in Osteosarcoma Chemo-Resistance.

Mol Ther. 2019-1-7

引用本文的文献

[1]
LncRNAs regulates cell death in osteosarcoma.

Sci Rep. 2025-7-2

[2]
Non-Coding RNAs in Diagnostic Pathology of High-Grade Central Osteosarcoma.

Diagnostics (Basel). 2025-5-28

[3]
Iron oxide nanoparticles coated with bioactive materials: a viable theragnostic strategy to improve osteosarcoma treatment.

Discov Nano. 2025-1-30

[4]
Radiomics analysis in differentiating osteosarcoma and chondrosarcoma based on T2-weighted imaging and contrast-enhanced T1-weighted imaging.

Sci Rep. 2024-11-4

[5]
Roles of LncRNA ARSR in tumor proliferation, drug resistance, and lipid and cholesterol metabolism.

Clin Transl Oncol. 2025-4

[6]
Delivery of miRNAs Using Nanoparticles for the Treatment of Osteosarcoma.

Int J Nanomedicine. 2024

[7]
Blocking CXCR4-CARM1-YAP axis overcomes osteosarcoma doxorubicin resistance by suppressing aerobic glycolysis.

Cancer Sci. 2024-10

[8]
Intelligent structure prediction and visualization analysis of non-coding RNA in osteosarcoma research.

Front Oncol. 2024-3-12

[9]
A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity.

J Exp Clin Cancer Res. 2024-2-21

[10]
Advancements in Understanding the Role of Circular RNA in Osteosarcoma.

Mol Biotechnol. 2024-9

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索